Research · 11 min read
How to Check Whether a Study a Company Cites Actually Exists
Most large trials of an FDA-regulated drug have to be in a public federal registry within 21 days of the first person enrolling, and results have to follow within a year of the primary completion date. Here is how to look one up, and the four situations where a real study is legitimately absent.
Key takeaways
- Registration information for a covered trial is due no later than 21 calendar days after the first human subject is enrolled.
- An applicable drug clinical trial must be interventional, of a phase other than phase 1, studying an FDA-regulated drug product, with a named U.S. connection — all four at once.
- Phase 1 trials, observational studies, non-FDA-regulated products and trials without a U.S. connection are outside the requirement, so their absence proves nothing.
- Results information is generally due within one year of the primary completion date, with a certification route that can move the deadline and a two-year outer bound.
- Submitted information must not be false or misleading in any particular, and failures are prohibited acts under the Federal Food, Drug, and Cosmetic Act.
- Each trial has exactly one responsible party — the sponsor, unless a principal investigator who controls the data and holds the right to publish is designated.
- A registry record is a declaration of design and timing, not peer review and not an FDA finding about the product.
Answer first: there is a registry, and it is checkable in seconds
Federal regulation requires certain clinical trials to be registered on ClinicalTrials.gov, the registry and results data bank the National Library of Medicine runs. Each registered trial gets an identifier beginning with the letters NCT.
That identifier is the thing to ask for. A citation that gives a journal name, a year and a number of participants can be checked only by someone with library access. An NCT number can be checked by anyone in about ten seconds.
Two deadlines run the system. Registration information is due no later than 21 calendar days after the first human subject is enrolled. Results information is generally due no later than one year after the trial's primary completion date.
And the submission itself is regulated for honesty. The rule states that clinical trial information submitted by a responsible party shall not be false or misleading in any particular. A party who submits false or misleading information is subject to civil monetary penalties, and to other civil or criminal remedies available under federal law.
Which trials actually have to be there
This is where most misreadings start, so it is worth taking the definition literally. For a study started on or after January 18, 2017, a trial is an applicable drug clinical trial when it meets four conditions at once.
The study type is interventional. The study phase is other than phase 1. The trial studies a U.S. FDA-regulated drug product. And at least one of three location conditions applies. A facility location in the United States or a territory. A product manufactured in and exported from the United States for study abroad. Or an FDA investigational new drug number on the trial.
Every one of those has to be true. Miss any of them and the trial is outside the requirement, however real and however large it is.
There is a parallel definition for devices. It turns on an interventional study of an FDA-regulated device product with a primary purpose other than a feasibility study, plus a similar location test. It also covers a pediatric postmarket surveillance FDA has ordered.
The four ways a real study is legitimately missing
Read the definition backwards and it tells you exactly when a genuine study will not be in the registry. An absence is not evidence that a company invented something.
It is a phase 1 trial. The definition excludes phase 1 outright. Early human safety and dosing work is real research, and it is not an applicable clinical trial.
It is observational rather than interventional. A study that watches what happens without assigning a treatment fails the first condition.
It studies something that is not an FDA-regulated drug or device product. A study of a diet, a coaching program or a supplement may not clear that bar.
It has no U.S. connection of the kind the rule names — no U.S. facility, no U.S.-manufactured export under study, no IND number.
So the useful question is not "is it in the registry". It is "which of those four boxes does this study sit in, and does the company's description of it match". A company describing a large randomized trial of a prescription drug conducted in the United States is describing something the rule reaches.
How to run the check
Start by asking for or finding the NCT number. Companies citing registered trials generally have it, and journal articles print it.
Look the number up on the registry. A number that does not exist returns a plain not-found response rather than a plausible-looking page, which is why this check is worth doing rather than assuming.
Then read five fields on the record, because they are the ones a marketing summary tends to smooth over. Study type, which should read interventional if the claim is about an effect of a treatment. Phase. Overall status. Enrollment, and whether that number is actual or estimated. And the lead sponsor.
Look next at whether results have been posted, and when. The record carries separate dates for when results were first submitted and when they were first posted, and those are not the same day.
A worked example makes the timing concrete. The cardiovascular outcomes trial registered as NCT03574597, listed under the acronym SELECT with Novo Nordisk A/S as lead sponsor, records a study type of interventional, phase 3, and an actual enrollment of 17,604. Its actual primary completion date is recorded as 21 June 2023. Results were first submitted on 18 June 2024 — three days inside the one-year deadline — and first posted on 30 August 2024.
That gap between submission and posting is normal and worth knowing about. Results go through a quality review before they appear publicly, so a trial can be compliant and still show nothing on the day the deadline passes.
Who is answerable for the record
Each trial has exactly one responsible party, and the rule says how that is determined.
The sponsor is the responsible party unless and until a principal investigator is designated instead. Where a trial runs under an investigational new drug application or an investigational device exemption, the holder of that application is the sponsor. Where it does not, the sponsor is the single person or entity who initiates the trial by preparing or planning it and who has authority and control over it.
A principal investigator may be designated only if four things are true. They are responsible for conducting the trial. They have access to and control over the data. They have the right to publish the results, and they can meet the submission and updating requirements.
That third condition is the interesting one for a reader judging a study. The right to publish is a condition of being the named responsible party, so the registry record tells you something about who controlled the data.
If a designated investigator stops meeting those conditions, the sponsor must withdraw the designation, and the sponsor becomes the responsible party again.
When results can lawfully be late
One-year-from-primary-completion is the general rule, and there is a documented way to postpone it that a reader should recognize rather than treat as a violation.
The deadline moves if the responsible party makes a certification before it passes. The certification states that the trial involves an already-approved drug or device, that the manufacturer is the sponsor, and that an application seeking approval of the studied use has been or will within a year be filed with FDA.
It becomes 30 calendar days after the earliest of three events. FDA approves the product for the use studied. FDA issues a letter ending the review cycle without approving that use. Or the application is withdrawn without resubmission for at least 210 calendar days.
There is an outer bound. Even with that certification, results must be submitted no later than two years after the certification was submitted.
A waiver route also exists, handled through a separate section of the rule. So a trial with no results posted is worth reading carefully rather than reading as concealment — but the reasons are enumerated, and the enumeration is public.
What happens when the rule is broken
The consequences are unusually concrete for a disclosure rule, and they run through food and drug law rather than through the registry itself.
Failure to submit required clinical trial information is a prohibited act. So is failing to submit the required certification that the requirements have been met, or knowingly submitting a false one. So is submitting clinical trial information that is false or misleading in any particular. Each of those is tied to a specific paragraph of section 301(jj) of the Federal Food, Drug, and Cosmetic Act.
A person who violates that section is subject to civil monetary penalties under the Act's penalty provision.
There is also a funding lever. Where a trial is funded in whole or part by the Department of Health and Human Services, required grant or progress report forms must carry a certification that all registration and results submissions have been made. If that cannot be verified, remaining and future grant funding is not released, and the grantee gets notice and 30 days to fix it.
What a registry record does not tell you
A record proves the trial was declared, by whom, with what design, and on what schedule. It is not a quality judgment.
It is not peer review. Nobody at the registry evaluated whether the design answers the question the company says it answers.
It is not an FDA finding. Registration is required for many trials that never support an approval, and a posted result is not an agency conclusion about the product.
It is not a guarantee that the marketing summary matches. The most common gap is not a fabricated study but a real study described as though it showed something adjacent to what it measured. The registry gives you the declared primary outcome, which is the thing to compare a claim against.
And it does not cover everything. The four-condition definition above is the boundary, and a claim resting on a phase 1 trial, an observational study or a program that is not an FDA-regulated product sits outside it by design.
Sources
- 42 CFR Part 11 — Clinical Trials Registration and Results Information SubmissionSection 11.2 for the purpose of the part, its statutory basis in section 402(j) of the Public Health Service Act, and the identification of ClinicalTrials.gov as the registry and results data bank established by the National Library of Medicine. Section 11.4 for the single-responsible-party rule, the determination of sponsor including the IND and IDE holder rule, the four conditions for designating a principal investigator, and withdrawal of that designation. Section 11.6 for the requirement that submitted information not be false or misleading in any particular and the exposure to civil monetary penalties and other remedies. Section 11.22(b)(2) for the four conditions defining an applicable drug clinical trial and 11.22(b)(1) for the device definition; 11.22(a)(3) for initiation being the date the first human subject is enrolled. Section 11.24(a) for the 21-calendar-day registration deadline. Section 11.42 for which trials require results information. Section 11.44(a) for the one-year standard deadline, (b)(1) for the certification route and its three triggering events including the 210-calendar-day withdrawal condition, and (b)(2) for the two-year limitation. Section 11.54 for the existence of a waiver procedure. Section 11.66 for the prohibited acts under section 301(jj) of the Federal Food, Drug, and Cosmetic Act, the civil monetary penalty provision, and the grant-funding consequence with its 30-day notice.
- ClinicalTrials.gov study record NCT03574597 (SELECT), API v2The worked example. Official title recorded as SELECT — Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity; lead sponsor Novo Nordisk A/S, class INDUSTRY; responsible party type SPONSOR; study type INTERVENTIONAL; phase PHASE3; actual enrollment 17,604; actual primary completion date 21 June 2023; results first submitted 18 June 2024; results first posted, actual, 30 August 2024. ⛔ Control in the same run: the same endpoint at NCT99999999 returned HTTP 404 at 32 bytes with the body "NCT number NCT99999999 not found", confirming the lookup distinguishes a real identifier from a well-formed invented one.
Frequently asked questions
What is an NCT number?
It is the identifier a trial receives when it is registered on ClinicalTrials.gov, the registry and results data bank the National Library of Medicine maintains under 42 CFR Part 11. It is the fastest way to check a citation, because a number that does not correspond to a registered trial returns a plain not-found response rather than a page that merely looks empty.
Does every study have to be registered?
No. For studies initiated on or after January 18, 2017, an applicable drug clinical trial must meet four conditions at once. The study type is interventional. The phase is other than phase 1. The trial studies a U.S. FDA-regulated drug product. And there is a U.S. connection: a facility location in the United States or a territory, a product manufactured in and exported from the United States for study abroad, or an FDA investigational new drug number. A trial that fails any one of those is outside the requirement.
If a study is not in the registry, was it made up?
Not necessarily, and it is worth resisting that jump. Phase 1 trials are excluded from the definition outright. So are observational studies, since the definition requires an interventional study type. So are studies of things that are not FDA-regulated drug or device products. So are trials with none of the named U.S. connections. The better question is which of those a given study falls into, and whether the company's description of it is consistent with that.
How soon after a trial ends should results appear?
The general deadline is no later than one year after the primary completion date. Submission and public posting are different events, though: results go through a review before they appear. On the SELECT cardiovascular outcomes trial, registered as NCT03574597, the record shows an actual primary completion date of 21 June 2023, results first submitted on 18 June 2024, and results first posted on 30 August 2024.
Can a company delay posting results?
Yes, through a defined route. The responsible party may certify, before the deadline, that the trial involves an already-approved product and that the manufacturer is the sponsor. The certification must also state that an application seeking approval of the studied use has been or will within a year be filed. The deadline then becomes 30 calendar days after the earliest of three events. FDA approving that use. FDA issuing a letter that ends the review cycle without approving it. Or the application being withdrawn without resubmission for at least 210 calendar days. Even then, results are due no later than two years after the certification was submitted. A separate waiver procedure also exists.
Who is responsible for what the record says?
Each trial has exactly one responsible party. The sponsor holds that role unless a principal investigator has been designated. That is allowed only where the investigator is responsible for conducting the trial, has access to and control over the data, has the right to publish the results, and can meet the submission requirements. Where a trial runs under an investigational new drug application, the holder of that application is the sponsor.
Is a registered trial a trial FDA endorsed?
No. Registration records that a trial was declared, by whom, with what design and on what timetable. It is not peer review and it is not an agency finding about the product. Many registered trials never support an approval. What the record is genuinely good for is comparing a marketing summary against the trial's own declared design and primary outcome.